Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype
about
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's diseaseOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisPharmacogenetics in inflammatory bowel diseaseRed cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.Sulphasalazine induced renal failureSensorimotor neuropathy with sulphasalazineMacrocytic anaemia in patients treated with sulphasalazine for rheumatoid arthritis.Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazideRaynaud's phenomenon induced by sulphasalazineMedical management of Crohn's disease: current therapy and recent advances.Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing Surveillance.Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions.Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study.Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?Palliative care in inflammatory bowel disease: an evidence-based approach.Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Combination therapy for autoimmune diseases: the rheumatoid arthritis model.Optimum dose of olsalazine for maintaining remission in ulcerative colitis.Drug therapy of ulcerative colitisDelayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report.Olsalazine in active ulcerative colitis.Incidence of sulphasalazine-induced male infertility.Assessment of the drug metabolism capacity of the liver.Salicylate induced exacerbation of ulcerative colitis.Sulphasalazine associated pancytopenia may be caused by acute folate deficiency.Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapseLongterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis.Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy.Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial.Review article: monitoring for drug side-effects in inflammatory bowel disease.Five-aminosalicylic Acid: an update for the reappraisal of an old drug
P2860
Q24185774-BA61A3F9-2C4C-4E39-B103-12A0E9A40FF7Q24185876-C577B422-5C5A-4085-BED8-C81816FD0A73Q24198024-D8147DFF-8EA8-4E80-B10D-CD9E45AFDC8EQ24198786-C52D893A-C137-482E-B3B6-10089EB52BE1Q24245127-0DC103B0-D60C-48E3-A62B-5F8E7F9B1187Q24246085-8B7F1753-D30D-4F35-BC42-73C642D799A3Q24246220-40B303E4-07B2-421A-981D-54DF49DE297FQ24248026-F00A0C9B-5459-49EE-8CE7-AF0AAEC9D815Q28246002-37648A49-3F3B-4A6E-ADA0-C14DACD82046Q28323157-DAF7D73C-B327-4DE0-B3C8-2EF6663E3071Q28327625-49A79B90-07F6-4F9A-B1EE-DC6484D605CCQ28360012-25E290A4-9AA4-48D2-A1C5-E74CB870A38EQ28360051-EE4628F7-6780-4613-BDEC-B7B0EE1D033AQ28361611-4373A503-D638-4575-9E5B-5125FBCFD9BFQ28365715-145B9ECF-FEE7-4D1C-967F-AE2BECFC53A9Q30450875-6C0C411A-9ED3-462A-9A40-DE2B9260AC0FQ30581062-79F0D589-FEEF-4D1A-8E64-1EA8CDF37AF1Q30993551-F3F47150-E2FA-4917-8A5B-B7FAE22D149FQ33396340-BDC737F4-89C7-4407-9947-1E1F32033680Q33401006-2E762713-EC34-479E-A1C7-DB3B2C5E70E9Q33538523-A9CAB5C5-E420-4D98-85A7-D6DFE23B0A32Q33868970-E793489D-6657-4A51-9A20-0D491FA852B2Q34015911-F38D1AE7-52B5-496C-B406-87A706407382Q34273329-DA465635-B04B-4EE4-8A4E-642DBB1663E1Q34309751-79329357-A0DC-4D6A-89B8-ECD5017678C8Q34382072-050FCCB3-F88D-4AB1-97C1-722C2EDEC79EQ34403155-38FEF696-404F-4198-B693-F5E27FC085C3Q34417836-AB1FC54A-577D-4763-8585-5A6FBF834A83Q34450198-A22FB937-A9CA-41F6-A392-F1D01710E5A2Q34492974-3494DEF5-31FE-4C1A-AA97-037829AFF01DQ34493772-CD5A87AE-0BF3-4B73-96E3-C0FB1757C673Q34511238-B52F07CF-B230-43D0-966C-5DF4BA501F83Q34527496-81703B94-3C41-4A15-B2AC-BAE024D6EBFCQ34529771-89E96506-010B-444D-BF43-5F420C79601CQ34530099-D870B107-BE9F-4C7F-BEBA-662BD284FCD0Q34530593-9150BD84-79B6-4155-9D9C-F98297C8ED4DQ34531735-4B1DA89B-5E7E-43D7-87AD-C13BC8F80119Q34532732-8BEB48A0-0EA6-4589-A473-5B44E0961201Q34585315-99EACE51-287D-4C8E-80A1-DBF4C0C8BDB5Q35061210-335A21FF-BDB3-477F-B6D3-6042592C953C
P2860
Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype
description
1973 nî lūn-bûn
@nan
1973 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1973 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1973年の論文
@ja
1973年論文
@yue
1973年論文
@zh-hant
1973年論文
@zh-hk
1973年論文
@zh-mo
1973年論文
@zh-tw
1973年论文
@wuu
name
Adverse reactions during salic ...... olism and acetylator phenotype
@ast
Adverse reactions during salic ...... olism and acetylator phenotype
@en
Adverse reactions during salic ...... olism and acetylator phenotype
@nl
type
label
Adverse reactions during salic ...... olism and acetylator phenotype
@ast
Adverse reactions during salic ...... olism and acetylator phenotype
@en
Adverse reactions during salic ...... olism and acetylator phenotype
@nl
prefLabel
Adverse reactions during salic ...... olism and acetylator phenotype
@ast
Adverse reactions during salic ...... olism and acetylator phenotype
@en
Adverse reactions during salic ...... olism and acetylator phenotype
@nl
P2093
P3181
P1476
Adverse reactions during salic ...... olism and acetylator phenotype
@en
P2093
P3181
P356
10.1056/NEJM197309062891001
P407
P577
1973-09-06T00:00:00Z